ICIs have become an advantageous treatment option for advanced or metastatic esophagogastric/EGJ cancer. Clinicians need to be aware of and understand the clinical trial data and real-world evidence supporting the use of ICIs, especially for treating MSI-H/dMMR tumors.

ICIs have become an advantageous treatment option for advanced or metastatic esophagogastric/EGJ cancer. Clinicians need to be aware of and understand the clinical trial data and real-world evidence supporting the use of ICIs, especially for treating MSI-H/dMMR tumors.

Clinicians need to be informed about the importance of MSI-H/dMMR testing in patients with GI tumors and updated on the most recent clinical evidence to ensure that they select the most appropriate treatment options for their patients.

Clinicians should be aware of the data supporting the use of immune checkpoint inhibitors, including nivolumab, in patients with various presentations of esophageal or esophagogastric junction cancers to identify the patients most likely to benefit from this treatment strategy.

Clinicians should regularly evaluate recent clinical trial data to make informed decisions on the most appropriate treatment plan, particularly as new targeted therapies, as well as new indications for existing targeted therapies, become FDA-approved.

The standards of care in the first-line setting for the treatment of advanced or metastatic esophageal, esophagogastric junction and gastric cancer are evolving rapidly. There is a need to review the current landscape of treatment regimens and understand how to incorporate the new standards of care to effectively treat this patient population.

Clinicians should regularly evaluate recent clinical trial data to make informed decisions on the most appropriate treatment plan, particularly as new targeted therapies, as well as new indications for existing targeted therapies, become FDA-approved.

The standards of care in the first-line setting for the treatment of advanced or metastatic esophageal, esophagogastric junction and gastric cancer are evolving rapidly. There is a need to review the current landscape of treatment regimens and understand how to incorporate the new standards of care to effectively treat this patient population.

Clinicians must consider disease stage, histology, biomarker expression and patient performance status to make decisions regarding optimal care of patients with esophageal cancer.